NCT02678299View on ClinicalTrials.gov

Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

February 28, 2022

Study Completion Date

December 31, 2025

Conditions
Malignant Lymphoma
Interventions
DRUG

PREBEN

Trial Locations (18)

2100

Department of Hematology, Copenhagen University Hospital, Copenhagen

5000

Department of Hematology, Odense University Hospital, Odense

7006

Department of Oncology, St. Olavs Hospital, Trondheim

DK-8200

Department of Hematology, Aarhus University Hospital, Aarhus

00029

Helsinki University Hospital Comprehensive Cancer Center, Helsinki

Unknown

Jeroen Bosch Hospital, 's-Hertogenbosch

Meander Medical Center, Amersfoort

Slingeland Hospital, Doetinchem

Albert Schweitzer Hospital, Dordrecht

Medisch Spectrum Twente, Enschede

Admiraal de Ruyter Hospital, Flushing

Universitair Medisch Centrum Groningen, Groningen

Spaarne Ziekenhuis, Hoofddorp

Erasmus Medical Center, Rotterdam

Haga Hospital, loc. Leyweg, The Hague

Stavanger University Hospital, Stavanger

0310

Department of Oncology, Oslo University Hospital, Oslo

221 85

Department of Oncology, Skåne University Hospital, Lund

All Listed Sponsors
lead

University of Aarhus

OTHER

NCT02678299 - Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study | Biotech Hunter | Biotech Hunter